ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links1 made here, not in the record7 judgments2 judges (the rules as one: Rule based)2 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07185997Study to Evaluate Efficacyand Safety of FirmonertinibCompared WithInvestigator's Choice ofEGFR Inhibitor asFirst-Line Treatment inParticipants Who HaveArriVent BioPharma, Inc.Phase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 14 · ClinicalTrials.gov record · Version of 2026-10-14Nov 2 · ClinicalTrials.gov record · Version of 2026-11-02Version of 2026-11-02CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionRespiratory Tract NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedBronchial NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedLung NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedDRUGSAflutinibEntry “Firmonertinib”, read by our na…›Nov 18 · Rule based · TestedTestedOsimertinibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Osimertinib

Made here1 judgment on this link
NCT07185997gives it, found by reading the recordOsimertinibDefined by Claude Opus 5.5Nov 3, 2026, 7:06 AM UTC
Role in the study, from the registry to what was judged
RegistryNot in the recordno intervention entry names it
→judged

All judgments on this study

WhenLinkJudgeDecisionState
Oct 14The record itselfClinicalTrials.gov recordVersion of 2026-10-14Record change
Nov 2The record itselfClinicalTrials.gov recordVersion of 2026-11-02Record change
Nov 3Osimertinibmade hereClaude Opus 5.5ComparatorCurrent
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 14Respiratory Tract NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Bronchial NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Lung NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 18AflutinibRule based · role ruleTestedCurrent
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.